Novo Nordisk CEO Maziar Mike Doustdar waits for the start of the pharmaceutical company’s annual general meeting in Copenhagen, Denmark, March 26, 2026.
Tom Little | Reuters
U.S.-traded shares of Novo Nordisk dropped more than 5% on Tuesday after the Danish drugmaker released guidance that appeared to disappoint investors.
The company hiked its 2026 outlook, saying it expects adjusted sales to be down 6% to flat at constant exchange rates. Novo Nordisk previously said it anticipated adjusted sales would fall between 4% to 12%.
The drugmaker also said it expects adjusted operating profit to be in a range of down 6% to flat. It had previously anticipated that metric would drop between 4% to 12%, as well.
Novo Nordisk also announced key financial metrics for the second quarter and first half of 2026, ahead of an expected earnings release on Wednesday. Eli Lilly, its lead rival in the booming market for GLP-1 drugs, will also post…
